contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


carasent-asa-has-completed-its-planned-cross-border-merger

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Carasent is an IT company. The company delivers a wide range of products and services in communication and IT infrastructure specifically aimed at the healthcare industry. Examples of solutions include proprietary cloud-based services, email management, mobile solutions, and security solutions. Customers are mainly found in health and care, finance, and telecom. The company was originally established in 1997 and is headquartered in Gothenburg.

Carasent

Carasent ASA has completed its planned cross-border merger with Carasent AB. Consequently, the last day of trading and listing of the Carasent ASA shares on Oslo Børs was 4 December 2024. The...

<div class="mfn-preamble"><p><strong>Carasent ASA has completed its planned cross-border merger with Carasent AB. Consequently, the last day of trading and listing of the Carasent ASA shares on Oslo Børs was 4 December 2024. The shares in Carasent AB are expected to start trading on Nasdaq Stockholm on 9 December 2024.</strong></p></div><div class="mfn-body"><p>As announced on 30 August 2024, the Carasent ASA board of directors has resolved on a cross-border merger plan to effect a planned relisting of its shares on Nasdaq Stockholm (the “<strong>Relisting</strong>”). Carasent ASA’s Extraordinary General Meeting approved the merger plan on 4 October 2024 as previously announced.</p><p>Upon completion of the merger, all Carasent shareholders had their shares in Carasent ASA exchanged one-for-one with shares in Carasent AB, and Carasent ASA is struck off from Oslo Børs. The shares in Carasent AB are expected to start trading on Nasdaq Stockholm on 9 December 2024.</p><p>For further information regarding the Relisting, please go to Carasent ASA’s website: <a rel="noopener" href="https://carasent.com/investors/relisting-to-nasdaq-stockholm-2024/">https://carasent.com/investors/relisting-to-nasdaq-stockholm-2024/</a>.</p><p><strong>For further information, please contact</strong></p><p>Daniel Öhman, CEO Tel: +46 70-855 37 07, or<br>Svein Martin Bjørnstad, CFO Tel: +47 979 69&nbsp;493</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-nsta"><p><em>This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication at 2024-12-05 07:51 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/eafb5d30-2c28-4a8e-8d45-84d796daa40e/carasent-asa-has-completed-its-planned-cross-border-merger.pdf" class="mfn-generated mfn-primary">Carasent ASA has completed its planned cross-border merger</a></p></div>

Carasent ASA has completed its planned cross-border merger

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Helsinki Stock Exchange is cheap

Drug development investment: Value creation through M&As and licensing agreements

Valuation methods: Valuation multiples

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!